П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to	C
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287

	0200	020.
Estimated average burde	en	
hours per response:		0.5

2. Issuer Name and Ticker or Trading Symbol Novus Therapeutics, Inc. [NVUS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u> </u>	X	Director	10% Owner		
3. Date of Earliest Transaction (Month/Day/Year) 06/13/2018		Officer (give title below)	Other (specify below)		
4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable				
	Line) X	,	1 0		
	Novus Therapeutics, Inc. [NVUS] 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2018	Novus Therapeutics, Inc. NVUS (Check X 3. Date of Earliest Transaction (Month/Day/Year) 06/13/2018 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indiv. 6. Indiv.	Novus Therapeutics, Inc. [NVUS] (Check all applicable) X Director 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) 06/13/2018 6. Individual or Joint/Group Filient 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filient X Form filed by One R Form filed by More t Form filed by More t		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any 🤺	3. Transa Code (8)		Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(3-,,,,														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Num of Deriva Securi Acquir (A) or Dispos of (D) (Instr. and 5)	tive ties red sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$6.18	06/13/2018		A		9,100		06/13/2019	06/13/2028	Common Stock	9,100	\$0.00	9,100	D	

Explanation of Responses:

Remarks:

/s/ Ryan A. Murr, as attorneyin-fact for Gary A. Lyons

06/14/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.